Week In Review: Hengrui And Degron Announce $7.2 Billion In Drug Licensings
May 25, 2024 at 17:00 PM EDT
Jiangsu Hengrui Medicine out-licensed global rights for its portfolio of three proprietary GLP-1 candidates to a US startup, Hercules, in a deal worth up to $6 billion. Hengrui will receive $110 million upfront and up to $200 million in milestones.
